Roche Diagnostics showcases powerful innovation at Arab Health

Roche Diagnostics showcases powerful innovation at Arab Health

Left: Moritz Hartmann, General Manager Roche Diagnostics Middle East, at the inauguration of the 41st Arab Health Exhibition with Shaikh Hamdan bin Rashid Al Maktoum, Deputy Ruler of Dubai and UAE Minister of Finance (Right).

Two significant technologies unveiled at Arab Health Exhibition & Congress 2016, which will assist healthcare professionals in driving increased standards of patient care.

Roche Diagnostics Middle East (RDME) unveiled two of the latest cobas family of products – the cobas e 801 module and cobas c 513 analyzer –at the Arab Health Exhibition & Congress 2016, the region’s largest event. Running between 25th to 28th January, the congress is the second largest event of its kind in the world, with over 115,000 people from over 161 countries and showcases the latest technological advances in gynaecology, paediatrics, orthopaedics, telehealth, robotics and ambulatory care, among other disciplines.

These new innovative instruments will further enable the region’s health care professionals and patients to make timely treatment decisions, upon receiving accurate diagnosis.

The cobas e 801, which will be capable of carrying out double the number of tests compared to the previous version, the cobas e 602, within the same laboratory space. The system requires smaller blood samples, making it particularly suitable for the diagnosis of vulnerable groups such as neonates, cancer and ICU patients and elderly people. At the same time, the reduced sample volume leads to less liquid waste, thereby minimizing environmental impact of the system. Commercial availability of the cobas e 801 module is planned for 2016*.

The cobas c 513 analyzer is a dedicated high-throughput HbA1c solution - suitable for monitoring of long-term blood glucose control in individuals with diabetes, to aid in diagnosis of diabetes and identification of patients at risk of developing diabetes. It sets new standards in terms of analytical performance, laboratory efficiency as well as saving laboratory space and enhancing the laboratory capability to report HbA1c results quickly. The direct results reporting negate the need to perform time consuming, manual result interpretation, saving valuable time, laboratory resources and maintaining high results quality. It is currently the only suitable solution for laboratories to manage a high HbA1c sample workload, to monitor, diagnose and identify patients at risk of diabetes.

Commenting on Roche’s participation in the Arab Health Exhibition & Congress 2016, Moritz Hartmann, General Manager of RDME said, “Arab Health provides the perfect launch pad for the cobas e 801 and cobas c 513, as diagnostics have become one of the most influential elements in healthcare provision. That’s why we strive through our continuous innovation to constantly increase testing efficiency, workflow integration, and breadth of diagnosis – enabling labs to provide test results while increasing accuracy and speed, thus empowering healthcare professionals and their patients to make informed decisions that are appropriate for them and their treatment journey.”

* CE Mark: Local product availability may vary independently from CE Mark approval.